The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects

Inclusion criteria

• males or females, aged 18-45.
• subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP<140mmHg; 50mmHg ≤DBP<90mmHg and 50 ≤ HR <110 beats / min.
• body mass index (BMI) between 18 to 28.
• Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters.

Exclusion criteria

• males or females, aged 18-45.
• subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP<140mmHg; 50mmHg ≤DBP<90mmHg and 50 ≤ HR <110 beats / min.
• body mass index (BMI) between 18 to 28.
• Participant in general good health. No clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters.

Exclusion criteria

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin > 1X ULN during screening/baseline.
• Serum creatinine> 1X ULN during screening/baseline.
• Abnormal coagulation function.
• A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs.
• Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening.
• Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration.
• Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive.

8.3 months prior to screening involved in any drug or medical device clinical studies or within 5 half-life of drugs before screening.

9.Female subjects who did not receive contraception at least 30 days before administration.